Radiopharm Theranostics LimitedASX: RAD

LOI with GenesisCare to start first trial in Australia

· Issued by Radiopharm Theranostics Limited

Filed with ASX · · 2 pages · English

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce it has agreed commercial terms for services in a signed Letter of Intent (LOI) with global oncology provider GenesisCare, whose support is critical to start Radiopharm’s first Phase 1 trial in Australi

Radiopharm Theranostics Limited on 6ix

Earlier from Radiopharm Theranostics

Later from Radiopharm Theranostics

All Radiopharm Theranostics news releases